A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma Model Article Swipe
Camille Jacques
,
Irene Marchesi
,
Francesco Paolo Fiorentino
,
Mathias Chatelais
,
Nicoletta Libera Lilli
,
Kurt Appel
,
Béatrice Lejeune
,
Ilaria Floris
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.3390/ijms23116059
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.3390/ijms23116059
In this study, the immunomodulatory effects of a sequential micro-immunotherapy medicine, referred as MIM-seq, were appraised in human primary M1 and M2 macrophages, in which the secretion of pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, IL-12, IL-23, and tumor necrosis factor (TNF)-alpha, was inhibited. In addition, the potential anti-proliferative effects of MIM-seq on tumor cells was assessed in three models of colorectal cancer (CRC): an in vitro two-dimensions (2D) model of HCT-116 cells, an in vitro tri-dimensional (3D) model of spheroids, and an in vivo model of subcutaneous xenografted mice. In these models, MIM-seq displayed anti-proliferative effects when compared with the vehicle. In vivo, the tumor growth was slightly reduced in MIM-seq-treated animals. Moreover, MIM-seq could slightly reduce the growth of our spheroid models, especially under serum-deprivation. When MIM-seq was combined with two well-known anti-cancerogenic agents, either resveratrol or etoposide, MIM-seq could even further reduce the spheroid’s volume, pointing up the need to further assess whether MIM-seq could be beneficial for CRC patients as an adjuvant therapy. Altogether, these data suggest that MIM-seq could have anti-tumor properties against CRC and an immunomodulatory effect towards the mediators of inflammation, whose systemic dysregulation is considered to be a poor prognosis for patients.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/ijms23116059
- https://www.mdpi.com/1422-0067/23/11/6059/pdf?version=1654074071
- OA Status
- gold
- Cited By
- 11
- References
- 82
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4281677966
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4281677966Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/ijms23116059Digital Object Identifier
- Title
-
A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma ModelWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-05-27Full publication date if available
- Authors
-
Camille Jacques, Irene Marchesi, Francesco Paolo Fiorentino, Mathias Chatelais, Nicoletta Libera Lilli, Kurt Appel, Béatrice Lejeune, Ilaria FlorisList of authors in order
- Landing page
-
https://doi.org/10.3390/ijms23116059Publisher landing page
- PDF URL
-
https://www.mdpi.com/1422-0067/23/11/6059/pdf?version=1654074071Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.mdpi.com/1422-0067/23/11/6059/pdf?version=1654074071Direct OA link when available
- Concepts
-
In vivo, Tumor necrosis factor alpha, Cancer research, In vitro, Medicine, Colorectal cancer, Immunotherapy, Inflammation, Adjuvant, Tumor microenvironment, Immunology, Cancer, Biology, Internal medicine, Tumor cells, Biotechnology, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
11Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3, 2024: 4, 2023: 4Per-year citation counts (last 5 years)
- References (count)
-
82Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4281677966 |
|---|---|
| doi | https://doi.org/10.3390/ijms23116059 |
| ids.doi | https://doi.org/10.3390/ijms23116059 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/35682738 |
| ids.openalex | https://openalex.org/W4281677966 |
| fwci | 1.29902724 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D002277 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Carcinoma |
| mesh[2].qualifier_ui | Q000188 |
| mesh[2].descriptor_ui | D003110 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | drug therapy |
| mesh[2].descriptor_name | Colonic Neoplasms |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D004195 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Disease Models, Animal |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D064593 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Heterografts |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D006801 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Humans |
| mesh[6].qualifier_ui | Q000494 |
| mesh[6].descriptor_ui | D007155 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | pharmacology |
| mesh[6].descriptor_name | Immunologic Factors |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D007167 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Immunotherapy |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D008264 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Macrophages |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D051379 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Mice |
| mesh[10].qualifier_ui | Q000494 |
| mesh[10].descriptor_ui | D014409 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | pharmacology |
| mesh[10].descriptor_name | Tumor Necrosis Factor-alpha |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000818 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Animals |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D002277 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Carcinoma |
| mesh[13].qualifier_ui | Q000188 |
| mesh[13].descriptor_ui | D003110 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | drug therapy |
| mesh[13].descriptor_name | Colonic Neoplasms |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D004195 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Disease Models, Animal |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D064593 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Heterografts |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D006801 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Humans |
| mesh[17].qualifier_ui | Q000494 |
| mesh[17].descriptor_ui | D007155 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | pharmacology |
| mesh[17].descriptor_name | Immunologic Factors |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D007167 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Immunotherapy |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D008264 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Macrophages |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D051379 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Mice |
| mesh[21].qualifier_ui | Q000494 |
| mesh[21].descriptor_ui | D014409 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | pharmacology |
| mesh[21].descriptor_name | Tumor Necrosis Factor-alpha |
| type | article |
| title | A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma Model |
| biblio.issue | 11 |
| biblio.volume | 23 |
| biblio.last_page | 6059 |
| biblio.first_page | 6059 |
| topics[0].id | https://openalex.org/T11313 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2403 |
| topics[0].subfield.display_name | Immunology |
| topics[0].display_name | Immune cells in cancer |
| topics[1].id | https://openalex.org/T10158 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9997000098228455 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Cancer Immunotherapy and Biomarkers |
| topics[2].id | https://openalex.org/T11355 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9983000159263611 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Inflammatory Biomarkers in Disease Prognosis |
| is_xpac | False |
| apc_list.value | 2300 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2490 |
| apc_paid.value | 2300 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2490 |
| concepts[0].id | https://openalex.org/C207001950 |
| concepts[0].level | 2 |
| concepts[0].score | 0.7842448353767395 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q141124 |
| concepts[0].display_name | In vivo |
| concepts[1].id | https://openalex.org/C17991360 |
| concepts[1].level | 2 |
| concepts[1].score | 0.5928570032119751 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q21173843 |
| concepts[1].display_name | Tumor necrosis factor alpha |
| concepts[2].id | https://openalex.org/C502942594 |
| concepts[2].level | 1 |
| concepts[2].score | 0.5899239778518677 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[2].display_name | Cancer research |
| concepts[3].id | https://openalex.org/C202751555 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5513706207275391 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[3].display_name | In vitro |
| concepts[4].id | https://openalex.org/C71924100 |
| concepts[4].level | 0 |
| concepts[4].score | 0.5295527577400208 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[4].display_name | Medicine |
| concepts[5].id | https://openalex.org/C526805850 |
| concepts[5].level | 3 |
| concepts[5].score | 0.4844253361225128 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q188874 |
| concepts[5].display_name | Colorectal cancer |
| concepts[6].id | https://openalex.org/C2777701055 |
| concepts[6].level | 3 |
| concepts[6].score | 0.4833376109600067 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[6].display_name | Immunotherapy |
| concepts[7].id | https://openalex.org/C2776914184 |
| concepts[7].level | 2 |
| concepts[7].score | 0.42673471570014954 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q101991 |
| concepts[7].display_name | Inflammation |
| concepts[8].id | https://openalex.org/C2777863537 |
| concepts[8].level | 2 |
| concepts[8].score | 0.41978126764297485 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q357896 |
| concepts[8].display_name | Adjuvant |
| concepts[9].id | https://openalex.org/C2776107976 |
| concepts[9].level | 3 |
| concepts[9].score | 0.41851356625556946 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1786433 |
| concepts[9].display_name | Tumor microenvironment |
| concepts[10].id | https://openalex.org/C203014093 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3667042553424835 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[10].display_name | Immunology |
| concepts[11].id | https://openalex.org/C121608353 |
| concepts[11].level | 2 |
| concepts[11].score | 0.3490619659423828 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[11].display_name | Cancer |
| concepts[12].id | https://openalex.org/C86803240 |
| concepts[12].level | 0 |
| concepts[12].score | 0.23345351219177246 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[12].display_name | Biology |
| concepts[13].id | https://openalex.org/C126322002 |
| concepts[13].level | 1 |
| concepts[13].score | 0.19306251406669617 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[13].display_name | Internal medicine |
| concepts[14].id | https://openalex.org/C3020616263 |
| concepts[14].level | 2 |
| concepts[14].score | 0.08106532692909241 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q1216998 |
| concepts[14].display_name | Tumor cells |
| concepts[15].id | https://openalex.org/C150903083 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7108 |
| concepts[15].display_name | Biotechnology |
| concepts[16].id | https://openalex.org/C55493867 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[16].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/in-vivo |
| keywords[0].score | 0.7842448353767395 |
| keywords[0].display_name | In vivo |
| keywords[1].id | https://openalex.org/keywords/tumor-necrosis-factor-alpha |
| keywords[1].score | 0.5928570032119751 |
| keywords[1].display_name | Tumor necrosis factor alpha |
| keywords[2].id | https://openalex.org/keywords/cancer-research |
| keywords[2].score | 0.5899239778518677 |
| keywords[2].display_name | Cancer research |
| keywords[3].id | https://openalex.org/keywords/in-vitro |
| keywords[3].score | 0.5513706207275391 |
| keywords[3].display_name | In vitro |
| keywords[4].id | https://openalex.org/keywords/medicine |
| keywords[4].score | 0.5295527577400208 |
| keywords[4].display_name | Medicine |
| keywords[5].id | https://openalex.org/keywords/colorectal-cancer |
| keywords[5].score | 0.4844253361225128 |
| keywords[5].display_name | Colorectal cancer |
| keywords[6].id | https://openalex.org/keywords/immunotherapy |
| keywords[6].score | 0.4833376109600067 |
| keywords[6].display_name | Immunotherapy |
| keywords[7].id | https://openalex.org/keywords/inflammation |
| keywords[7].score | 0.42673471570014954 |
| keywords[7].display_name | Inflammation |
| keywords[8].id | https://openalex.org/keywords/adjuvant |
| keywords[8].score | 0.41978126764297485 |
| keywords[8].display_name | Adjuvant |
| keywords[9].id | https://openalex.org/keywords/tumor-microenvironment |
| keywords[9].score | 0.41851356625556946 |
| keywords[9].display_name | Tumor microenvironment |
| keywords[10].id | https://openalex.org/keywords/immunology |
| keywords[10].score | 0.3667042553424835 |
| keywords[10].display_name | Immunology |
| keywords[11].id | https://openalex.org/keywords/cancer |
| keywords[11].score | 0.3490619659423828 |
| keywords[11].display_name | Cancer |
| keywords[12].id | https://openalex.org/keywords/biology |
| keywords[12].score | 0.23345351219177246 |
| keywords[12].display_name | Biology |
| keywords[13].id | https://openalex.org/keywords/internal-medicine |
| keywords[13].score | 0.19306251406669617 |
| keywords[13].display_name | Internal medicine |
| keywords[14].id | https://openalex.org/keywords/tumor-cells |
| keywords[14].score | 0.08106532692909241 |
| keywords[14].display_name | Tumor cells |
| language | en |
| locations[0].id | doi:10.3390/ijms23116059 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S10623703 |
| locations[0].source.issn | 1422-0067, 1661-6596 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1422-0067 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | International Journal of Molecular Sciences |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.mdpi.com/1422-0067/23/11/6059/pdf?version=1654074071 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | International Journal of Molecular Sciences |
| locations[0].landing_page_url | https://doi.org/10.3390/ijms23116059 |
| locations[1].id | pmid:35682738 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | International journal of molecular sciences |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/35682738 |
| locations[2].id | pmh:oai:doaj.org/article:2f765858aae7451bb8bda22b6919e868 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | International Journal of Molecular Sciences, Vol 23, Iss 6059, p 6059 (2022) |
| locations[2].landing_page_url | https://doaj.org/article/2f765858aae7451bb8bda22b6919e868 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:9181410 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Int J Mol Sci |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9181410 |
| locations[4].id | pmh:oai:mdpi.com:/1422-0067/23/11/6059/ |
| locations[4].is_oa | True |
| locations[4].source.id | https://openalex.org/S4306400947 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | True |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | MDPI (MDPI AG) |
| locations[4].source.host_organization | https://openalex.org/I4210097602 |
| locations[4].source.host_organization_name | Multidisciplinary Digital Publishing Institute (Switzerland) |
| locations[4].source.host_organization_lineage | https://openalex.org/I4210097602 |
| locations[4].license | cc-by |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | Text |
| locations[4].license_id | https://openalex.org/licenses/cc-by |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | International Journal of Molecular Sciences; Volume 23; Issue 11; Pages: 6059 |
| locations[4].landing_page_url | https://dx.doi.org/10.3390/ijms23116059 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5030896487 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-8044-0545 |
| authorships[0].author.display_name | Camille Jacques |
| authorships[0].affiliations[0].raw_affiliation_string | Preclinical Research Department, Labo’Life France, 1 rue François Bruneau, 44000 Nantes, France |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Camille Jacques |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Preclinical Research Department, Labo’Life France, 1 rue François Bruneau, 44000 Nantes, France |
| authorships[1].author.id | https://openalex.org/A5071899400 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-4383-6110 |
| authorships[1].author.display_name | Irene Marchesi |
| authorships[1].affiliations[0].raw_affiliation_string | Kitos Biotech s.r.l.s., Porto Conte Ricerche, S.P. 55 Porto Conte—Capo Caccia, Km 8,400 Loc. Tramariglio, 07041 Alghero, Italy |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Irene Marchesi |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Kitos Biotech s.r.l.s., Porto Conte Ricerche, S.P. 55 Porto Conte—Capo Caccia, Km 8,400 Loc. Tramariglio, 07041 Alghero, Italy |
| authorships[2].author.id | https://openalex.org/A5022958528 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-7547-2262 |
| authorships[2].author.display_name | Francesco Paolo Fiorentino |
| authorships[2].affiliations[0].raw_affiliation_string | Kitos Biotech s.r.l.s., Porto Conte Ricerche, S.P. 55 Porto Conte—Capo Caccia, Km 8,400 Loc. Tramariglio, 07041 Alghero, Italy |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Francesco Paolo Fiorentino |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Kitos Biotech s.r.l.s., Porto Conte Ricerche, S.P. 55 Porto Conte—Capo Caccia, Km 8,400 Loc. Tramariglio, 07041 Alghero, Italy |
| authorships[3].author.id | https://openalex.org/A5038295441 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Mathias Chatelais |
| authorships[3].affiliations[0].raw_affiliation_string | ProfileHIT, 7 rue du Buisson, 44680 Sainte-Pazanne, France |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mathias Chatelais |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | ProfileHIT, 7 rue du Buisson, 44680 Sainte-Pazanne, France |
| authorships[4].author.id | https://openalex.org/A5059223137 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-1606-4191 |
| authorships[4].author.display_name | Nicoletta Libera Lilli |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210128055 |
| authorships[4].affiliations[0].raw_affiliation_string | Centre d’Investigation Clinique Hématologie CHU Hôtel Dieu, 44093 Nantes, France |
| authorships[4].institutions[0].id | https://openalex.org/I4210128055 |
| authorships[4].institutions[0].ror | https://ror.org/02ct41845 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I154526488, https://openalex.org/I3019204325, https://openalex.org/I4210105774, https://openalex.org/I4210128055 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Centre d'Investigation Clinique de Nantes |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Nicoletta Libera Lilli |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Centre d’Investigation Clinique Hématologie CHU Hôtel Dieu, 44093 Nantes, France |
| authorships[5].author.id | https://openalex.org/A5052669069 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-4315-4478 |
| authorships[5].author.display_name | Kurt Appel |
| authorships[5].affiliations[0].raw_affiliation_string | VivaCell Biotechnology GmbH, 79211 Denzlingen, Germany |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Kurt Appel |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | VivaCell Biotechnology GmbH, 79211 Denzlingen, Germany |
| authorships[6].author.id | https://openalex.org/A5085089072 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-9067-6116 |
| authorships[6].author.display_name | Béatrice Lejeune |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210116042 |
| authorships[6].affiliations[0].raw_affiliation_string | InFlectis Bioscience, 44200 Nantes, France |
| authorships[6].institutions[0].id | https://openalex.org/I4210116042 |
| authorships[6].institutions[0].ror | https://ror.org/025mn7712 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210116042 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | InFlectis BioScience |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Beatrice Lejeune |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | InFlectis Bioscience, 44200 Nantes, France |
| authorships[7].author.id | https://openalex.org/A5008250826 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-4089-3133 |
| authorships[7].author.display_name | Ilaria Floris |
| authorships[7].affiliations[0].raw_affiliation_string | Preclinical Research Department, Labo’Life France, 1 rue François Bruneau, 44000 Nantes, France |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Ilaria Floris |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Preclinical Research Department, Labo’Life France, 1 rue François Bruneau, 44000 Nantes, France |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.mdpi.com/1422-0067/23/11/6059/pdf?version=1654074071 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma Model |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11313 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2403 |
| primary_topic.subfield.display_name | Immunology |
| primary_topic.display_name | Immune cells in cancer |
| related_works | https://openalex.org/W4251003423, https://openalex.org/W2386116568, https://openalex.org/W2944387023, https://openalex.org/W2378135797, https://openalex.org/W4200022043, https://openalex.org/W2112727616, https://openalex.org/W2884525857, https://openalex.org/W4322720888, https://openalex.org/W4296613612, https://openalex.org/W3193904228 |
| cited_by_count | 11 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 4 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 4 |
| locations_count | 5 |
| best_oa_location.id | doi:10.3390/ijms23116059 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S10623703 |
| best_oa_location.source.issn | 1422-0067, 1661-6596 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1422-0067 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | International Journal of Molecular Sciences |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.mdpi.com/1422-0067/23/11/6059/pdf?version=1654074071 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | International Journal of Molecular Sciences |
| best_oa_location.landing_page_url | https://doi.org/10.3390/ijms23116059 |
| primary_location.id | doi:10.3390/ijms23116059 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S10623703 |
| primary_location.source.issn | 1422-0067, 1661-6596 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1422-0067 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | International Journal of Molecular Sciences |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.mdpi.com/1422-0067/23/11/6059/pdf?version=1654074071 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | International Journal of Molecular Sciences |
| primary_location.landing_page_url | https://doi.org/10.3390/ijms23116059 |
| publication_date | 2022-05-27 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W1967628954, https://openalex.org/W2470575266, https://openalex.org/W3033043135, https://openalex.org/W3087639804, https://openalex.org/W1642873092, https://openalex.org/W2791130871, https://openalex.org/W2789767010, https://openalex.org/W2193610649, https://openalex.org/W3039645032, https://openalex.org/W2754943127, https://openalex.org/W2003390592, https://openalex.org/W6714781504, https://openalex.org/W1950572133, https://openalex.org/W1965037168, https://openalex.org/W2144320908, https://openalex.org/W2969361551, https://openalex.org/W2579357550, https://openalex.org/W2898452876, https://openalex.org/W3119842691, https://openalex.org/W2990687775, https://openalex.org/W3013168088, https://openalex.org/W3001321031, https://openalex.org/W4200059482, https://openalex.org/W4212924766, https://openalex.org/W3175541122, https://openalex.org/W2053531492, https://openalex.org/W2005120878, https://openalex.org/W3157215841, https://openalex.org/W6707673697, https://openalex.org/W1917881935, https://openalex.org/W2399585527, https://openalex.org/W3097021382, https://openalex.org/W2582686270, https://openalex.org/W2947075883, https://openalex.org/W2112940058, https://openalex.org/W3029645031, https://openalex.org/W3006485077, https://openalex.org/W2626049567, https://openalex.org/W2345434428, https://openalex.org/W2029161990, https://openalex.org/W3146206569, https://openalex.org/W2171813323, https://openalex.org/W2117692326, https://openalex.org/W2992809542, https://openalex.org/W2168470080, https://openalex.org/W1514134885, https://openalex.org/W2123504951, https://openalex.org/W2783686102, https://openalex.org/W2364298751, https://openalex.org/W2999711650, https://openalex.org/W1986396469, https://openalex.org/W6641474725, https://openalex.org/W2589489476, https://openalex.org/W2078950332, https://openalex.org/W2087750317, https://openalex.org/W3192824725, https://openalex.org/W1975916906, https://openalex.org/W3119125259, https://openalex.org/W1976899534, https://openalex.org/W2033750865, https://openalex.org/W2011396843, https://openalex.org/W2051907464, https://openalex.org/W2012385670, https://openalex.org/W1632595063, https://openalex.org/W2068758713, https://openalex.org/W3212745443, https://openalex.org/W2020433921, https://openalex.org/W2626004372, https://openalex.org/W2090179518, https://openalex.org/W2410818381, https://openalex.org/W3021404331, https://openalex.org/W2054775930, https://openalex.org/W3080312648, https://openalex.org/W3011177534, https://openalex.org/W2102217547, https://openalex.org/W2914548578, https://openalex.org/W3119252947, https://openalex.org/W2915956078, https://openalex.org/W3110964033, https://openalex.org/W1965183553, https://openalex.org/W3094416885, https://openalex.org/W2954723822 |
| referenced_works_count | 82 |
| abstract_inverted_index.a | 7, 195 |
| abstract_inverted_index.In | 0, 44, 90, 102 |
| abstract_inverted_index.M1 | 19 |
| abstract_inverted_index.M2 | 21 |
| abstract_inverted_index.an | 64, 73, 82, 164, 180 |
| abstract_inverted_index.as | 12, 31, 163 |
| abstract_inverted_index.be | 158, 194 |
| abstract_inverted_index.in | 16, 23, 57, 65, 74, 83, 110 |
| abstract_inverted_index.is | 191 |
| abstract_inverted_index.of | 6, 27, 50, 60, 70, 79, 86, 120, 186 |
| abstract_inverted_index.on | 52 |
| abstract_inverted_index.or | 138 |
| abstract_inverted_index.to | 152, 193 |
| abstract_inverted_index.up | 149 |
| abstract_inverted_index.CRC | 161, 178 |
| abstract_inverted_index.and | 20, 37, 81, 179 |
| abstract_inverted_index.for | 160, 198 |
| abstract_inverted_index.our | 121 |
| abstract_inverted_index.the | 3, 25, 46, 100, 104, 118, 145, 150, 184 |
| abstract_inverted_index.two | 132 |
| abstract_inverted_index.was | 42, 55, 107, 129 |
| abstract_inverted_index.(2D) | 68 |
| abstract_inverted_index.(3D) | 77 |
| abstract_inverted_index.When | 127 |
| abstract_inverted_index.data | 169 |
| abstract_inverted_index.even | 142 |
| abstract_inverted_index.have | 174 |
| abstract_inverted_index.need | 151 |
| abstract_inverted_index.poor | 196 |
| abstract_inverted_index.such | 30 |
| abstract_inverted_index.that | 171 |
| abstract_inverted_index.this | 1 |
| abstract_inverted_index.vivo | 84 |
| abstract_inverted_index.were | 14 |
| abstract_inverted_index.when | 97 |
| abstract_inverted_index.with | 99, 131 |
| abstract_inverted_index.IL-6, | 34 |
| abstract_inverted_index.cells | 54 |
| abstract_inverted_index.could | 115, 141, 157, 173 |
| abstract_inverted_index.human | 17 |
| abstract_inverted_index.mice. | 89 |
| abstract_inverted_index.model | 69, 78, 85 |
| abstract_inverted_index.these | 91, 168 |
| abstract_inverted_index.three | 58 |
| abstract_inverted_index.tumor | 38, 53, 105 |
| abstract_inverted_index.under | 125 |
| abstract_inverted_index.vitro | 66, 75 |
| abstract_inverted_index.vivo, | 103 |
| abstract_inverted_index.which | 24 |
| abstract_inverted_index.whose | 188 |
| abstract_inverted_index.(CRC): | 63 |
| abstract_inverted_index.IL-12, | 35 |
| abstract_inverted_index.IL-23, | 36 |
| abstract_inverted_index.assess | 154 |
| abstract_inverted_index.cancer | 62 |
| abstract_inverted_index.cells, | 72 |
| abstract_inverted_index.effect | 182 |
| abstract_inverted_index.either | 136 |
| abstract_inverted_index.factor | 40 |
| abstract_inverted_index.growth | 106, 119 |
| abstract_inverted_index.models | 59 |
| abstract_inverted_index.reduce | 117, 144 |
| abstract_inverted_index.study, | 2 |
| abstract_inverted_index.HCT-116 | 71 |
| abstract_inverted_index.MIM-seq | 51, 93, 114, 128, 140, 156, 172 |
| abstract_inverted_index.against | 177 |
| abstract_inverted_index.agents, | 135 |
| abstract_inverted_index.effects | 5, 49, 96 |
| abstract_inverted_index.further | 143, 153 |
| abstract_inverted_index.models, | 92, 123 |
| abstract_inverted_index.primary | 18 |
| abstract_inverted_index.reduced | 109 |
| abstract_inverted_index.suggest | 170 |
| abstract_inverted_index.towards | 183 |
| abstract_inverted_index.volume, | 147 |
| abstract_inverted_index.whether | 155 |
| abstract_inverted_index.MIM-seq, | 13 |
| abstract_inverted_index.adjuvant | 165 |
| abstract_inverted_index.animals. | 112 |
| abstract_inverted_index.assessed | 56 |
| abstract_inverted_index.combined | 130 |
| abstract_inverted_index.compared | 98 |
| abstract_inverted_index.necrosis | 39 |
| abstract_inverted_index.patients | 162 |
| abstract_inverted_index.pointing | 148 |
| abstract_inverted_index.referred | 11 |
| abstract_inverted_index.slightly | 108, 116 |
| abstract_inverted_index.spheroid | 122 |
| abstract_inverted_index.systemic | 189 |
| abstract_inverted_index.therapy. | 166 |
| abstract_inverted_index.vehicle. | 101 |
| abstract_inverted_index.(IL)-1β, | 33 |
| abstract_inverted_index.Moreover, | 113 |
| abstract_inverted_index.addition, | 45 |
| abstract_inverted_index.appraised | 15 |
| abstract_inverted_index.displayed | 94 |
| abstract_inverted_index.mediators | 185 |
| abstract_inverted_index.medicine, | 10 |
| abstract_inverted_index.patients. | 199 |
| abstract_inverted_index.potential | 47 |
| abstract_inverted_index.prognosis | 197 |
| abstract_inverted_index.secretion | 26 |
| abstract_inverted_index.anti-tumor | 175 |
| abstract_inverted_index.beneficial | 159 |
| abstract_inverted_index.colorectal | 61 |
| abstract_inverted_index.considered | 192 |
| abstract_inverted_index.cytokines, | 29 |
| abstract_inverted_index.especially | 124 |
| abstract_inverted_index.etoposide, | 139 |
| abstract_inverted_index.inhibited. | 43 |
| abstract_inverted_index.properties | 176 |
| abstract_inverted_index.sequential | 8 |
| abstract_inverted_index.spheroids, | 80 |
| abstract_inverted_index.well-known | 133 |
| abstract_inverted_index.Altogether, | 167 |
| abstract_inverted_index.interleukin | 32 |
| abstract_inverted_index.resveratrol | 137 |
| abstract_inverted_index.xenografted | 88 |
| abstract_inverted_index.(TNF)-alpha, | 41 |
| abstract_inverted_index.macrophages, | 22 |
| abstract_inverted_index.spheroid’s | 146 |
| abstract_inverted_index.subcutaneous | 87 |
| abstract_inverted_index.dysregulation | 190 |
| abstract_inverted_index.inflammation, | 187 |
| abstract_inverted_index.two-dimensions | 67 |
| abstract_inverted_index.MIM-seq-treated | 111 |
| abstract_inverted_index.tri-dimensional | 76 |
| abstract_inverted_index.immunomodulatory | 4, 181 |
| abstract_inverted_index.pro-inflammatory | 28 |
| abstract_inverted_index.anti-cancerogenic | 134 |
| abstract_inverted_index.anti-proliferative | 48, 95 |
| abstract_inverted_index.serum-deprivation. | 126 |
| abstract_inverted_index.micro-immunotherapy | 9 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 97 |
| corresponding_author_ids | https://openalex.org/A5030896487 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 8 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/1 |
| sustainable_development_goals[0].score | 0.5400000214576721 |
| sustainable_development_goals[0].display_name | No poverty |
| citation_normalized_percentile.value | 0.73836146 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |